ArticleClinical neuroscience research2002
Mood stabilizer psychopharmacology.
Article in Clinical neuroscience research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Comprehensive Review and Meta-Analysis of Psychological and Pharmacological Treatment for Intermittent Explosive Disorder: Insights From Both Case Studies and Randomized Controlled Trials.Clinical psychology & psychotherapyPooled it
- Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances.Current medicinal chemistry · 2026Review
- Chemotherapy-Induced Remodeling of the Gut Microbiota-Inflammation Axis: Implications for the Course of Bipolar Disorder.Journal of multidisciplinary healthcare · 2026Review
- Ketogenic-Mimicking Diet as a Therapeutic Modality for Bipolar Disorder: Biomechanistic Rationale and Protocol for a Pilot Clinical Trial.Nutrients · 2023Article
- Understanding the medication safety challenges for patients with mental illness in primary care: a scoping review.BMC psychiatry · 2023Article
- Current and Possible Future Therapeutic Options for Huntington's Disease.Journal of central nervous system disease · 2022Review
- The Impact of Lithium on Brain Function in Bipolar Disorder: An Updated Review of Functional Magnetic Resonance Imaging Studies.CNS drugs · 2021Review
- Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms.The pharmacogenomics journal · 2021Article
- Valproic acid stimulatesStem cell investigation · 2019Article
- NOX2-Dependent Reactive Oxygen Species Regulate Formyl-Peptide Receptor 1-Mediated TrkA Transactivation in SH-SY5Y Cells.Oxidative medicine and cellular longevity · 2019Article
- Animal models to improve our understanding and treatment of suicidal behavior.Translational psychiatry · 2017Review
- A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts.Neuropsychiatric disease and treatment · 2016Review
- Search for common targets of lithium and valproic acid identifies novel epigenetic effects of lithium on the rat leptin receptor gene.Translational psychiatry · 2015Article
- Potential application of lithium in Parkinson's and other neurodegenerative diseases.Frontiers in neuroscience · 2015Review
- Molecular actions and clinical pharmacogenetics of lithium therapy.Pharmacology, biochemistry, and behavior · 2014Review
- Lithium, but not valproate, reduces impulsive choice in the delay-discounting task in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Potential mechanisms of action of lithium in bipolar disorder. Current understanding.CNS drugs · 2013Review
- Autophagy and polyglutamine diseases.Progress in neurobiology · 2012Review
- Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects.Neuropsychobiology · 2010Review
- Lithium induces autophagy by inhibiting inositol monophosphatase.The Journal of cell biology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Mood stabilizers represent a class of drugs that are efficacious in the treatment of bipolar disorder. The most established medications in this class are lithium, valproic acid, and carbamazepine. In addition to their therapeutic effects for treatment of acute manic episodes, these medications often are useful as prophylaxis against future episodes and as adjunctive antidepressant medications. While important extracellular effects have not been excluded, most available evidence suggests that the therapeutically relevant targets of this class of medications are in the interior of cells. Herein we give a prospective of a rapidly evolving field, discussing common effects of mood stabilizers as well as effects that are unique to individual medications. Mood stabilizers have been shown to modulate the activity of enzymes, ion channels, arachidonic acid turnover, G protein coupled receptors and intracellular pathways involved in synaptic plasticity and neuroprotection. Understanding the therapeutic targets of mood stabilizers will undoubtedly lead to a better understanding of the pathophysiology of bipolar disorder and to the development of improved therapeutics for the treatment of this disease. Furthermore, the involvement of mood stabilizers in pathways operative in neuroprotection suggests that they may have utility in the treatment of classical neurodegenerative disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.